Patents Assigned to Triton Biosciences, Inc.
  • C-erbB-2 exrernal domain: gp75
    Publication number: 20020155527
    Abstract: Disclosed are methods and compositions for identifying malignant tumors that overexpress the c-erbB-2 oncogene. Assays useful for diagnosis and prognosis of neoplastic disease are provided which detect the external domain of c-erbB-2, the glycoprotein gp75 and quantitate the level of gp75 in the biological fluids of mammals carrying a tumor burden.
    Type: Application
    Filed: January 26, 2001
    Publication date: October 24, 2002
    Applicant: Triton BioSciences, Inc.
    Inventors: Susan G. Stuart, John J. Monahan, Beatrice Claudia Langton, Miriam E. C. Hancock, Lorrine A. Chao, Peter Bluford
  • Peptides representing epitopic sites for the major HTLV-I envelope protein, antibodies thereto, and uses thereof
    Patent number: 5003043
    Abstract: The present invention discloses synthetic peptides and antibodies raised thereto wherein the synthetic peptides represent important epitopic sites recognized by the 0.5 .alpha. antibody, a human monoclonal antibody which can neutralize HTLV-I. Also, the uses of these peptides or antibodies thereto either alone or in combination with peptides representing the epitopic site for the predominant antibodies found in HTLV-I env seropositive sera as diagnostics, therapeutics and vaccines are disclosed.
    Type: Grant
    Filed: May 25, 1988
    Date of Patent: March 26, 1991
    Assignee: Triton Biosciences Inc.
    Inventors: Robert W. Akita, Dagne L. Florine, John S. Ralston
  • HTLV-I anti-sense RNA and encoded proteins
    Patent number: 4999421
    Abstract: The mRNA coded by the "anti-sense" strand of the complementary DNA produced by HTLV-I infection contains significant open reading frames. Cells infected by HTLV-I virus produce mRNA that is anti-sense to the viral RNA genome. Infected cells may produce proteins from the newly discovered mRNA. The production of the anti-sense in mRNA initiates from a newly discovered transcriptional promoter located within 1.8 kb from the 3' terminus of the viral genome. The mRNA, protein, and antibodies directed thereto can be used in the prevention, diagnosis, and treatment of HTLV-I infections.
    Type: Grant
    Filed: June 27, 1988
    Date of Patent: March 12, 1991
    Assignee: Triton Biosciences Inc.
    Inventors: Terence K. Brunck, David J. Larocca, John J. Monahan
  • Peptides affecting blood pressure regulation
    Patent number: 4772684
    Abstract: Peptides of the formula: ##STR1## wherein: NH is the .alpha. amino group of amino acid AA.sup.1 ; ##STR2## is the carbonyl group of amino acid AA.sup.7 ; X is H--, ##STR3## GLU-VAL-, or VAL-TYR-HIS-GLU-VAL; Y is --OH, --NH.sub.2, or --PRO; AA.sup.1 is LYS, GLU, GLN, pGLU, .beta.ALA, PRO, PRO-OH, PIC, or AIB; AA.sup.2 is VAL, LEU, ILE, MET, or AIB; AA.sup.3 is ASP, TYR, GLU, HIS, or PHE; AA.sup.4 is VAL, MET, ILE, LEU, or AIB; AA.sup.5 is TYR, HIS, or GLU; AA.sup.6 is ALA, PRO, SER, .beta.ALA, PRO-OH, or AIB; and AA.sup.7 is VAL, LEU, ILE, or AIB;and salts thereof are claimed as effective blood pressure regulators. Further provided, are antibodies to these peptides, as well as diagnostic and therapeutic methods for blood pressure regulation.
    Type: Grant
    Filed: February 18, 1988
    Date of Patent: September 20, 1988
    Assignee: Triton Biosciences, Inc.
    Inventors: Terence K. Brunck, Clarence Colby, Jr.